Express Pharma

MAY 11, 2025

Accretion Pharmaceuticals, an Ahmedabad-headquartered pharmaceuticals manufacturer, announced that its initial public offering (IPO) will open for subscription on Wednesday, May 14, 2025. The anchor portion will be opened on Tuesday, May 13, 2025, and the issue will conclude on Friday, May 16, 2025.

Pharmaceutical Manufacturing

PharmaVoice

JUNE 23, 2025

Published June 23, 2025 Amy Baxter Staff Reporter post share post print email license Stock via Getty Images Listen to the article 6 min This audio is auto-generated. Mounjaro reached nearly $12 billion in revenue last year, while Jardiance, Lilly’s diabetes medication co-owned with Boehringer Ingelheim, topped $10 billion for the year.

Diabetes

European Pharmaceutical Review

JULY 24, 2025

Anticipated drug approvals in Q3 2025 As such, other drug authorisations are expected to follow in Q3 2025, such as Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd) for adult growth hormone deficiency (GHD). Clinical data for diabetes supports the drug’s potential as an obesity medicine, stated GlobalData.

Chemotherapy

Pharma Marketing Network

JUNE 21, 2025

In 2025, the landscape of healthcare marketing is evolving faster than ever—and nowhere is this more evident than on social media. In 2025, pharma brands are shifting toward engagement-first models that prioritize dialogue over monologue. Moreover, 2025 has seen a surge in partnerships with health influencers and patient advocates.

Prescription Filling

Pharma Times

JUNE 30, 2025

Mansard House Church Road Little Bookham Leatherhead Surrey KT23 3JG E: editorial@pharmatimes.com E: subscriptions@pharmatimes.com T: +44 (0)20 7240 6999 F: +44 (0)20 7240 4479 Get the latest pharma news delivered to your inbox A valid email address is required.

Diabetes

Express Pharma

AUGUST 10, 2025

Glucagon is indicated for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus. As per IQVIA MAT June 2025 data, Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit, had estimated annual sales of USD 122 million in the United States.

Packaging

Pharma Marketing Network

JULY 14, 2025

Let’s unpack the evolving challenges—and opportunities—shaping pharmaceutical branding in 2025 and beyond. One of the biggest branding hurdles in 2025 is maintaining trust and transparency in digital spaces. Regulatory Complexity and Global Brand Management Launching a global pharmaceutical brand in 2025 requires more than translation.

Biosimilars

Pharma Marketing Network

NOVEMBER 15, 2024

Example: When marketing a new diabetes medication like Ozempic , your content should be tailored to answer specific questions patients or HCPs might have about the drug. What are the top platforms for pharma marketing in 2025? Pharma professionals should take the time to research and segment their audience.

Diabetes

Express Pharma

JULY 23, 2025

As of March 2025, the committed investment of ₹17,275 crore targeted over the six-year period of the scheme has substantially exceeded with a cumulative investment of ₹37,306 crore made by the scheme’s third year, and cumulative sales of approved products of ₹2,66,528 crore have been made, including exports of ₹1,70,807 crore.

Pharmaceutical Companies

PharmaVoice

JULY 31, 2025

Published July 31, 2025 Meagan Parrish Lead Editor post share post print email license Incoming Novo Nordisk CEO, Maziar Mike Doustdar Permission granted by Novo Nordisk Listen to the article 5 min This audio is auto-generated. By Alexandra Pecci • July 29, 2025 Keep up with the story. © 2025 TechTarget, Inc.

Diabetes

Express Pharma

DECEMBER 2, 2024

The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.

Labelling

Pharmacy Times

JULY 28, 2025

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

Diabetes

Pharma Marketing Network

JULY 30, 2025

The digital marketing playbook for pharma has undergone a seismic shift in 2025, driven largely by one of the most disruptive forces in search: AI Overviews. Here are several approaches being used in 2025: 1. As 2025 continues to unfold, those who adapt will not just rank higher—they’ll lead the conversation.

Labelling

Express Pharma

JULY 24, 2025

It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza) had an estimated annual sale of USD 458 million in the US (IQVIA MAT May 2025).

Diabetes

Express Pharma

MARCH 2, 2025

Union Minister of Chemicals and Fertilizers, and Health and Family Welfare, Jagat Prakash Nadda inaugurated the weeklong celebrations of Jan Aushadhi Diwas, 2025 by flagging off the Rath (Chariot) and 10 other vehicles carrying the information about Pradhan Mantri Bhartiya Janaushadhi Pariyojana from Nirman Bhawan. to the citizens.

Generic Medicine

Pharmacy Times

JULY 16, 2025

That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.

Vaccines

pharmaphorum

JUNE 12, 2025

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Health and Personal Care Stores

Pharma Marketing Network

JUNE 16, 2025

In this article, we’ll explore the most effective HCP targeting strategies shaping pharma marketing in 2025—from data segmentation and digital tools to content personalization and compliance. In 2025, HCP targeting helps brands focus their resources on high-value providers—those most likely to prescribe, influence peers, or educate patients.

HIPAA

Express Pharma

MARCH 16, 2025

For example, companies like Biocon and Cipla have introduced affordable biosimilars and cost-effective versions of critical treatments for conditions such as diabetes and cancer. What are the top 3 trends to watch out for in 2025,which could have a disproportionate impact on the globaland Indian life sciences landscape?

Biosimilars

Express Pharma

JUNE 26, 2025

The company has set a revenue target of ₹100 crore for the financial year 2025–26, following a 100 per cent year-on-year growth from ₹20 crore in FY23–24 to ₹40 crore in FY24–25. In a recent move, Kashmik launched Dapagliflozin under the DAPNEC brand in the anti-diabetic segment.

Pharmaceutical Manufacturing

PharmaVoice

JULY 7, 2025

Published July 7, 2025 Amy Baxter Staff Reporter post share post print email license stock via Getty Images Listen to the article 6 min This audio is auto-generated. Estimates vary for how many patients with either obesity or diabetes stop using the drugs, but one 2024 study pegged the discontinuation between 50% and 75% within a year.

Compounding

PharmD Live

JANUARY 8, 2025

Medicares increasing focus on quality metrics in 2025 presents critical challenges for healthcare providers. Reporting Deadline: Data for the 2024 performance year must be submitted by March 31, 2025, to avoid penalties and secure incentives. This underscores the urgency of compliance in subsequent years.

Hospitals

Pharmacy Times

JULY 12, 2025

Innovative pharmacist-led care models—from tech-enabled Afib screenings and HPV immunizations to Medicare-supported diabetes prevention—demonstrate how pharmacies are redefining their role in team-based clinical care.

Diabetes

The Pharmacist

JULY 14, 2025

The FreeStyle Libre 2 Sensor – a glucose monitoring system manufactured by Abbott Laboratories – is set to be discontinued in August 2025, with the product to be removed from Part IX of the October 2025 Drug Tariff.

Diabetes

PharmaVoice

JULY 8, 2025

Published July 8, 2025 By Kelly Bilodeau post share post print email license Stock via Getty Images Listen to the article 5 min This audio is auto-generated. And if you can do that, cancer becomes a chronic, manageable disease, like diabetes, cardiac disease or HIV. By Amy Baxter • July 7, 2025 Keep up with the story.

Immunity

Big Molecule Watch

JULY 29, 2025

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., KIRSTY is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. KIRSTY will be available in the U.S.

Biosimilars

Pharmacy Times

AUGUST 6, 2025

Immunize.org.Updated July 3, 2025. Accessed July 16, 2025. Accessed July 16, 2025. Accessed July 16, 2025. The conversations grounded in pharmacy expertise and public health principles support healthier classrooms, stronger communities, and a more confident return to learning. REFERENCES 1. Vaccine-specific requirements.

Vaccines

Quality Matters

JULY 28, 2025

The EU alone significantly dominates production for critical brand therapeutic classes like general anesthetics (90%), non-insulin diabetes drugs (86%), and antithrombotics (73%). pharmaceutical supply chain. in 2024, along with the disease types they treat and representative drug products in each class.

Diabetes

Pharma Marketing Network

AUGUST 6, 2025

Fast forward to 2025, and display advertising has transformed into a data-driven, omnichannel engine of precision engagement. Ads for Ozempic , for instance, may perform better when shown alongside content related to diabetes management or cardiovascular risk reduction. Context also matters.

Insurance Coverage and Processing

Express Pharma

APRIL 8, 2025

Novo Nordisk has released full results from the SOUL cardiovascular outcomes trial, a phase 3b study evaluating the impact of oral semaglutide on adults with type 2 diabetes who also have cardiovascular disease (CVD) and/or chronic kidney disease (CKD). Notably, participants from the Asian region showed a 27 per cent reduction in MACE risk.

Diabetes

Commonwealth Pharmacists Association

JUNE 30, 2025

The pharmacist in Malaysia, inspiring global peers with their fresh approach to diabetes care. The CPA Academy launches in July 2025. The early-career practitioner in Ghana, using data and design tools to reshape antimicrobial use in their community. These are the outcomes that matter, and they’re only just beginning.

Health and Personal Care Stores

Pharmacy Times

JUNE 20, 2025

Related Videos Related Content Advertisement June 20th 2025 FDA Approves Dupilumb for Treatment of Bullous Pemphigoid Aislinn Antrim, Managing Editor May 28th 2025 Pharmacy Focus: Navigating Seasonal Allergies Luke Halpern, Assistant Editor Derek Webb, PharmD June 20th 2025 Self-Care Measures for Preventing and Managing Dysmenorrhea Yvette C.

Vaccines

Pharmacy Times

JUNE 24, 2025

Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting. Pharmacy Times : Can you share an overview of what you discussed at OPC 2025? Author(s): Alexandra Gerlach, Associate Editor , Scott A.

Pharmacy Technician

Pharma Marketing Network

AUGUST 6, 2025

For example, if prescription trends show a spike in Farxiga (dapagliflozin) for Type 2 diabetes in a specific region, a campaign can prioritize providers in that area. Likewise, digital behaviors—such as keyword searches or formulary checks—can trigger relevant messaging on medical journals, search engines, or social media.

HIPAA

Pharmacy Times

JULY 16, 2025

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, showcased significant advances across a range of malignancies, with novel agents, biomarker-driven strategies, and long-term outcomes data offering new insights into cancer treatment with implications for pharmacy practice.

HIV Treatment and Prevention Agents

European Pharmaceutical Review

APRIL 18, 2025

“ ACHIEVE-1 is the first of seven Phase III studies examining the safety and efficacy of orforglipron across people with diabetes and obesity. This demonstrates promising potential for patients, as seven percent is regarded as the diabetes threshold by the American Diabetes Association’s (ADA).

Diabetes

Pharma Marketing Network

JUNE 13, 2025

By Max Kopp Diabetes care is entering a new era—yet even in 2025, continuous glucose monitors (CGMs) remain out of reach for millions. Despite a decade of innovation, current CGMs often fail to meet the needs of everyday people with type 2 diabetes, particularly those in under-resourced or underserved communities.

Diabetes